My Mutation Has No Approved Drug — — What Comes Next?

A molecular tumour board is a meeting of oncologists, pathologists, molecular biologists, and geneticists who review complex tumour reports together and make a shared recommendation. It is most useful when a report shows a rare mutation, a variant of uncertain significance, or a result that does not fit a standard treatment pathway — which is exactly the situation this page describes. Ask your oncologist whether your case has been or will be reviewed at one. You do not attend the meeting yourself; the team reviews your case and reports the recommendation back to your treating oncologist.

Possibly, and it is worth exploring before ruling it out. The US, UK, Singapore, and South Korea run large numbers of mutation-matched trials, and some actively recruit patients internationally. The practical questions are whether you are well enough to travel for regular dosing visits, what the cost would be, and whether your care can be co-managed with a team in India. Some international trials allow most monitoring visits to happen locally, with only key assessments abroad. Your oncologist can write to the trial site on your behalf to ask about this.

In most cases your oncologist can give you an initial answer within one to two weeks of receiving the molecular report — the major trial registries are searchable and most oncologists familiar with molecular medicine check them regularly. At CION centres, molecular results are reviewed at regular multidisciplinary team meetings. If you have not had any answer within two weeks of receiving the report, ask your oncologist specifically for an update on the trial search and whether the case has been reviewed by a tumour board.

Not necessarily, but it is reasonable to ask. Not every centre has the same depth of molecular oncology expertise, and some oncologists are more familiar with trial registries than others. Asking directly — has this mutation been reviewed at a tumour board, and have we searched for clinical trials? — is a completely appropriate question. If you are not satisfied with the answer, seeking a second opinion at a comprehensive cancer centre with a dedicated molecular oncology programme is a recognised and sensible step.

Yes, unless your oncologist has a specific reason to pause it. Waiting for a molecular tumour board recommendation or trial eligibility confirmation can take a few weeks, and in most cases standard treatment should continue during that time. Stopping effective treatment to wait for a trial that may not accept you is rarely the right approach. Your oncologist will tell you if there is a specific reason to hold treatment — for example, if trial eligibility requires being treatment-naive — but that would be the exception, not the default.

We do not know, and anyone who gives you a confident answer either way is speculating. What we do know is that the pace of approval for mutation-matched drugs has accelerated significantly over the past decade, and mutations that were once considered untargetable — including some KRAS variants — now have approved drugs or late-stage trials. Following your oncologist's advice on re-testing and keeping the clinical trial question open gives you the best chance of benefiting from approvals as they happen.